Insmed generated $819.6M in trailing twelve-month revenue, up 1.2% year-over-year. Net income was -$1.2B with a -144.44% net margin. Gross margin stands at 81.81% and operating margin at -140.56%. Diluted EPS is $-5.76, which grew 0.0% year-over-year. Based on the Q1 2026 filing.